Company intelligence / Profile preview

ReViral

London, United Kingdomleadiq.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ReViral's lead candidate RV521 has received approval to proceed with development for treating RSV, which affects up to 64 million people annually, particularly infants, the elderly, and immunocompromised individuals[3].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antiviral therapies)
Industry: Biotech

Drug pipeline

1 asset

sisunatovir

Phase 2

Indications: Respiratory syncytial virus infection

Beyond the preview

Go deeper on ReViral.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReViral.

Explore the full profile